Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06832618 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Study acronym: TRuE-AD5
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion moved earlier from May 18, 2028 to Sep 6, 2027 Primary completion date changed from estimate of Jul 13, 2026 to Aug 7, 2026v26 Show 1 more changeShow less
    • Primary completion date changed from estimate of Jul 13, 2026 to Aug 7, 2026
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 240 to confirmed 159 · Study sites: 96 to 93v25 Show 2 more changesShow less
    • Enrollment target: estimated 240 to confirmed 159
    • Study sites: 96 to 93
  3. Study sites revised (96)v24 See this version in full on ClinicalTrials.gov ↗
  4. Site details revised at 5 of 96 sitesv23
  5. Study sites: 95 to 96v22
Show 20 earlier versionsHide 20 earlier versions
  1. Study sites: 97 to 95v21
  2. Study sites revised (97)v20 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (97)v19 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 96 to 97v18
  5. Study sites: 94 to 96v17
  6. Study sites: 93 to 94v16
  7. Study sites: 90 to 93v15
  8. Study sites revised (90)v14 See this version in full on ClinicalTrials.gov ↗
  9. Study sites: 95 to 90v13
  10. Study sites revised (95)v12 See this version in full on ClinicalTrials.gov ↗
  11. Study sites revised (95)v11 See this version in full on ClinicalTrials.gov ↗
  12. Study sites: 93 to 95v10
  13. Study sites revised (93)v9 See this version in full on ClinicalTrials.gov ↗
  14. Study sites: 92 to 93v8
  15. Site details revised at 1 of 92 sitesv7
  16. Re-verified, no change to tracked fieldsv6
  17. Start date changed from estimate of Jul 14, 2025 to Jun 17, 2025 Study sites revised (92)v5 Show 1 more changeShow less
    • Study sites revised (92)

    See this version in full on ClinicalTrials.gov ↗

  18. Start date: May 28, 2025 to Jul 14, 2025 Study sites: 91 to 92v4 Show 1 more changeShow less
    • Study sites: 91 to 92
  19. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 91v3 Show 1 more changeShow less
    • Study sites: 0 to 91
  20. Study Status, Referencesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
Atopic Dermatitis
491 trials monitored
See 14 trials at risk
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Trial Details
NCT Number NCT06832618
Lead Sponsor Incyte Corporation
Conditions Atopic Dermatitis
Enrollment 159 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov